<DOC>
	<DOCNO>NCT01419717</DOCNO>
	<brief_summary>This trial facilitate access denosumab subject advance cancer participate denosumab phase 3 study denosumab approve available sale , another mechanism identify provide denosumab ongoing subject .</brief_summary>
	<brief_title>Open-Label Access Protocol Denosumab Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subject previously enrol denosumab phase 3 study participate Openlabel Extension portion study . Subject subject 's legally acceptable representative provide informed consent . Subject child bear potential planning become pregnant within 7 month end treatment . Subject child bear potential willing use , combination partner , two highly effective method contraception treatment 7 month end treatment . Subject know sensitivity product administer dosing . Subject available protocol require study visit procedure , best subject investigator 's knowledge . Subject kind disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply require study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>breast cancer</keyword>
	<keyword>prostate cancer</keyword>
</DOC>